CLLS CELLECTIS - ADR

Ownership history in MARSHALL WACE, LLP  ·  9 quarters on record

This page tracks every 13F SEC filing in which MARSHALL WACE, LLP reported a position in CELLECTIS - ADR (CLLS). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.01% (2019 Q2)
Avg. % of fund
0.0%
First filed
2019 Q2
Last filed
2025 Q4
Quarters held
9
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 178,473 +168,038 +1610.3% 0.00% $864K $4.84
2025 Q3 REDUCED 10,435 -98,309 -90.4% 0.00% $30K $2.85
2022 Q3 REDUCED 108,744 -5,697 -5.0% 0.00% $249K $2.29
2022 Q2 REDUCED 114,441 -31,757 -21.7% 0.00% $324K $2.83
2022 Q1 ADDED 146,198 +140,714 +2565.9% 0.00% $663K $4.54
2021 Q4 REDUCED 5,484 -32,988 -85.7% 0.00% $44K $8.12
2020 Q2 ADDED 38,472 +22,229 +136.9% 0.00% $685K $17.80
2019 Q3 REDUCED 16,243 -33,241 -67.2% 0.00% $169K $10.40
2019 Q2 INITIATED 49,484 0.01% $772K
% of Fund (quarterly)    CLLS price (monthly, adj. close)
← Back to MARSHALL WACE, LLP Holdings